Treating Tumors Using TTFields Combined with ABT-751
Viability of cancer cells (e.g., glioblastoma cells) can be reduced by administering ABT-751 to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz (e.g., 200 kHz) to the cancer cells. Notably, experiments show that the combination of ABT-751 and the alternating electric field produces synergistic results for certain glioblastoma cell lines.
1 . A method of reducing viability of cancer cells, the method comprising:
administering ABT-751 to the cancer cells; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz.
2 . The method of claim 1 , wherein at least a portion of the applying step is performed simultaneously with at least a portion of the administering step.
3 . The method of claim 1 , wherein the ABT-751 comprises a pharmaceutically acceptable carrier.
4 . The method of claim 1 , wherein the applying step has a duration of at least 72 hours.
5 . The method of claim 1 , wherein the applying step has a duration of at least 8 hours.
6 . The method of claim 1 , wherein the applying step comprises applying the alternating electric field for at least three intervals of at least 16 hours each, with a break between each of the at least three intervals during which alternating electric fields are not applied.
7 . The method of claim 1 , wherein the frequency of the alternating electric field is 200 kHz.
8 . The method of claim 1 , wherein the ABT-751 is administered to the cancer cells at a therapeutically effective concentration, and wherein the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells.
9 . The method of claim 1 , wherein the cancer cells comprise glioblastoma cells.